Business Context and Reporting Period
Company: Bionexus Gene Lab Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2020
Event: The Company conducted a live webcast PowerPoint presentation at the Life Sciences Investor Forum. The presentation was delivered by Dr. Stephen Ponnampalam, Chief Medical Officer, and is filed as Exhibit 99.1.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the occurrence of the investor presentation.
Material Changes
No material changes to financial position or operations are reported in this document. The filing is limited to the disclosure of the corporate event described in Item 8.01.
Guidance, Outlook, and Risks
- Outlook: The presentation included forward-looking statements regarding the Company's strategies to develop and commercialize its RNA technology, as well as the safety and efficacy of said technology.
- Risks: The filing cautions that forward-looking statements are subject to risks detailed in the Company's Form 10-K for the fiscal year ended December 31, 2019.
- Disclaimer: The Company disclaims any obligation to update the information contained in this report or the presentation, except as required by applicable law.
Key Facts for Investor Verification
- Verify the content of the PowerPoint presentation filed as Exhibit 99.1 for specific details on RNA technology development.
- Review the Form 10-K for the fiscal year ended December 31, 2019, to understand the risk factors associated with the forward-looking statements.
- Note that the information provided is current only as of December 17, 2020, and may not reflect subsequent events.